Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women
Launched by UNIVERSITY OF COLORADO, DENVER · May 28, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
The "Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information" study is looking into why some women might not want to receive personalized information about their risk of breast cancer, especially in relation to mammogram screenings. This research is important because it aims to help improve how we communicate cancer risk to women, enabling them to make better-informed decisions about their health.
To participate in this study, you must be a woman aged between 39 and 49 who can read and understand English. However, if you have had breast cancer before, certain types of non-invasive breast cancer, or specific genetic conditions, you won't be eligible to join. If you take part, you will help researchers learn more about the challenges women face when it comes to understanding their breast cancer risk, which could lead to better support and resources for others in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Female sex
- • 2. Age 39-49 (i.e., people who are eligible for routine breast cancer screening and for whom guidelines recommend an informed, risk-based decision)
- • 3. English literacy
- Exclusion Criteria:
- • 1. Prior diagnosis of
- • 1. breast cancer
- • 2. Ductal carcinoma in situ (DCIS)
- • 3. Lobular carcinoma in situ (LCIS)
- • 4. Known BRCA1/2 gene mutation
- • 5. Cowan syndrome
- • 6. Li-Fraumeni syndrome
- • 7. Having received previous chest radiation for treatment of Hodgkin's lymphoma.
Trial Officials
Laura Scherer, PhD
Principal Investigator
University of Colorado, Denver
Erika Waters, PhD
Principal Investigator
Washington University at St. Louis
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Saint Louis, Missouri, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0